Results from ALTA-IL trial show Alunbrig reduced disease progression risk by 50% compared to Xalkori for ALK+ NSCLC.- Takeda

Takeda Pharmaceutical Company Limited announced results from the Phase III ALTA-1L (ALK in Lung Cancer Trial of BrigAtinib in 1st Line) trial , demonstrating that Alunbrig reduced the risk of disease progression or death, known as progression-free survival (PFS), as assessed by a blinded independent review committee (BIRC), by more than fifty percent compared to crizotinib (Xalkori) in adults with anaplastic lymphoma kinase-positive (ALK+) locally advanced or metastatic non-small cell lung cancer (NSCLC) who had not received a prior ALK inhibitor.

Findings from the first interim analysis of the ALTA-1L trial were presented during the Presidential Symposium at the International Association for the Study of Lung Cancer (IASLC) 19th World Conference on Lung Cancer (WCLC) in Toronto on Tuesday, September 25, 2018. The data were also simultaneously published online in The New England Journal of Medicine. Alunbrig is currently not approved as first-line therapy for advanced ALK+ NSCLC.

Treatment with Alunbrig resulted in superior PFS compared to crizotinib as assessed by a blinded independent review committee (hazard ratio = 0.49 [95 percent confidence interval(CI), 0.33 to 0.74]; log-rank p=0.0007), corresponding to a 51 percent reduction in the risk of disease progression or death. The safety profile associated with Alunbrig was generally consistent with the existing U.S.prescribing information.

See- "Brigatinib versus Crizotinib in ALK-Positive Non�Small-Cell Lung Cancer"-D. Ross Camidge, M.D., Ph.D., Hye Ryun Kim, M.D., Ph.D., Myung-Ju Ahn, M.D., Ph.D., et al.-September 25, 2018 DOI: 10.1056/NEJMoa1810171.